A Case of Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma

Intern Med. 2022 Apr 2. doi: 10.2169/internalmedicine.9261-21. Online ahead of print.ABSTRACTParathyroid carcinoma (PC) is a rare type of endocrine cancer. Recurrence and metastasis are common after surgery, and refractory hypercalcemia often leads to a poor prognosis. However, there are currently no specific strategies for PC recurrence. We herein report a 61-year-old Japanese man with metastatic PC who was treated with sorafenib, a multikinase inhibitor. In this case, the serum calcium level was under control for 10 months after the initiation of sorafenib. This case suggests that combination therapy with sorafenib, evocalcet, and denosumab may be an alternative, stronger management option for refractory hypercalcemia in recurrent PC.PMID:35370235 | DOI:10.2169/internalmedicine.9261-21

Source: Cancer Control - April 4, 2022 Category: Cancer & Oncology Authors: Hirofumi Makino Masakazu Notsu Itsuko Asayama Hazuki Otani Miwa Morita Masahiro Yamamoto Mika Yamauchi Mika Nakao Hitomi Miyake Asuka Araki Shinya Uchino Keizo Kanasaki Source Type: research